AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16621882 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group overall outcomes
Number of subjects: 1810
Study 12755837 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 40 mg
Number of subjects: 0
Study 12755837 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg
Number of subjects: 0
Study 12755837 — intervention group
Group type: COMPARATOR
Intervention: Helicobacter pylori eradication
Number of subjects: 0
Study 10323634 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer-driven outreach program
Number of subjects: 163
Study 10323634 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further contact)
Number of subjects: 163
Study 10323634 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunization delay of longer than 30 days at enrollment
Number of subjects: 163
Study 8731665 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical all‐trans retinoic acid (0.1%)
Number of subjects: 7
Study 8731665 — intervention group
Group type: COMPARATOR
Intervention: Topical sodium lauryl sulphate (2%)
Number of subjects: 7
Study 8731665 — intervention group
Group type: COMPARATOR
Intervention: Vehicle creams
Number of subjects: 7
Study 1656739 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg on day 1 followed by 250 mg/day for days 2-5)
Number of subjects: 78
Study 1656739 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (500 mg three times daily for 10 days)
Number of subjects: 78
Study 1656739 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 78
Study 1656739 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 78
Study 6277019 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine
Number of subjects: 65
Study 6277019 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine
Number of subjects: 65
Study 30704508 — intervention group
Group type: COMPARATOR
Intervention: Early care bundle intervention including early and comprehensive management of symptoms, prompt detection and treatment of precipitating factors, intravenous nitrate boluses, low-dose diuretics, non-invasive ventilation, and preventive low-molecular-weight heparin.
Number of subjects: 15
Study 30704508 — intervention group
Group type: COMPARATOR
Intervention: Control period (standard care) for 2 weeks before switching to intervention.
Number of subjects: 15
Study 28103945 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluralaner topical solution
Number of subjects: 221
Study 28103945 — intervention group
Group type: COMPARATOR
Intervention: Positive control (fipronil/(S)‐methoprene)
Number of subjects: 221
Study 26009229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 884
Study 26009229 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 884
Study 26009229 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (control)
Number of subjects: 884
Study 23403682 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (14-day lansoprazole, amoxicillin, and clarithromycin)
Number of subjects: 1463
Study 23403682 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (5-day lansoprazole and amoxicillin followed by 5-day lansoprazole, clarithromycin, and metronidazole)
Number of subjects: 1463
Study 23403682 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant therapy (5-day lansoprazole, amoxicillin, clarithromycin, and metronidazole)
Number of subjects: 1463
Study 23403682 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall effectiveness considering all missing UBT results as positive
Number of subjects: 1463
Study 23403682 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-treatment with 14-day bismuth-based quadruple therapy
Number of subjects: 1463
Study 23403682 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonadherence to initial therapy
Number of subjects: 1463
Study 23403682 — intervention group
Group type: EXPERIMENTAL
Intervention: Children in the household
Number of subjects: 1463
Study 23403682 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-treatment course analysis
Number of subjects: 1463
Study 22111592 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily mixed nutritional supplement (SUP, ∼5.1 MJ·d⁻¹)
Number of subjects: 30
Study 22111592 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 30
Study 19695390 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirodenafil 100 mg
Number of subjects: 20
Study 19695390 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol 0.5 g/kg
Number of subjects: 20
Study 19695390 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirodenafil + Alcohol
Number of subjects: 20
Study 19695390 — intervention group
Group type: COMPARATOR
Intervention: Mirodenafil
Number of subjects: 20
Study 17946394 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation model of glucose-insulin system
Number of subjects: 204
Study 17946394 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-loop insulin infusion strategy
Number of subjects: 204
Study 17946394 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin infusion strategy
Number of subjects: 204
Study 15087582 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention for dementia caregivers
Number of subjects: 128
Study 11511139 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone
Number of subjects: 82
Study 11511139 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide therapy
Number of subjects: 82
Study 11511139 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone therapy
Number of subjects: 82
Study 10166900 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐help manuals alone (M)
Number of subjects: 63
Study 10166900 — intervention group
Group type: EXPERIMENTAL
Intervention: self‐help manuals and incentives for 6 months (IM)
Number of subjects: 63
Study 10166900 — intervention group
Group type: EXPERIMENTAL
Intervention: maintenance manuals, incentives and cognitive‐behavioral support groups for 6 months (GIM)
Number of subjects: 63
Study 8438780 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet (628 kJ.kg-1.d-1 with 15% of total energy as protein)
Number of subjects: 69
Study 8438780 — intervention group
Group type: COMPARATOR
Intervention: Standard-protein diet (isoenergetic with 7.5% of total energy as protein)
Number of subjects: 69
Study 8438780 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 69
Study 8438780 — intervention group
Group type: COMPARATOR
Intervention: Standard-protein diet
Number of subjects: 69
Study 3427807 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifonazole 1% solution applied once daily for 1 day
Number of subjects: 90
Study 3427807 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifonazole 1% solution applied once daily for 2 days (day one and day three)
Number of subjects: 90
Study 3427807 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifonazole 1% solution applied once daily for 3 days (day one, day three and day six)
Number of subjects: 90
Study 30040057 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting balloon (DEB) percutaneous transluminal angioplasty (PTA)
Number of subjects: 119
Study 30040057 — intervention group
Group type: COMPARATOR
Intervention: Conventional balloon PTA (cPTA)
Number of subjects: 119
Study 27381857 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 night of total sleep deprivation in healthy young adults (N = 58)
Number of subjects: 112
Study 27381857 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 nights of partial sleep deprivation (5 hours sleep opportunity) in healthy young adults and adolescents (N = 54)
Number of subjects: 112
Study 25335648 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 315
Study 25335648 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 315
Study 23558673 — intervention group
Group type: EXPERIMENTAL
Intervention: IMRT with XELOX chemotherapy
Number of subjects: 65
Study 23558673 — intervention group
Group type: COMPARATOR
Intervention: 3D-CRT with 5-FU/FA chemotherapy
Number of subjects: 65
Study 20504298 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 3 x 400 mg oral for three days
Number of subjects: 80
Study 20504298 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 2 x 250 mg (+1 placebo) oral for three days
Number of subjects: 80
Study 20504298 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 80
Study 20504298 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 80
Study 18536783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (110 microg once daily)
Number of subjects: 0
Study 18536783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray
Number of subjects: 0
Study 16737938 — intervention group
Group type: EXPERIMENTAL
Intervention: Ex vivo T cell‐depleted bone marrow transplantation
Number of subjects: 0
Study 16737938 — intervention group
Group type: COMPARATOR
Intervention: Conventional marrow transplantation (methotrexate and cyclosporine immunosuppression)
Number of subjects: 0
Study 14646157 — intervention group
Group type: EXPERIMENTAL
Intervention: Minilaparotomy
Number of subjects: 60
Study 14646157 — intervention group
Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 60
Study 10972945 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent magnetic field exposure (127.3 microT)
Number of subjects: 24
Study 10972945 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous magnetic field exposure (127.3 microT)
Number of subjects: 24
Study 10972945 — intervention group
Group type: COMPARATOR
Intervention: No-exposure control condition
Number of subjects: 24
Study 8986060 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (300 MBq of 99mTc‐ECD)
Number of subjects: 44
Study 8986060 — intervention group
Group type: COMPARATOR
Intervention: Placebo (physiological saline)
Number of subjects: 44
Study 1295724 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodropropizine (60 mg and 90 mg)
Number of subjects: 8
Study 1295724 — intervention group
Group type: EXPERIMENTAL
Intervention: Dropropizine (60 mg and 90 mg)
Number of subjects: 8
Study 1295724 — intervention group
Group type: COMPARATOR
Intervention: Control (no drug administration)
Number of subjects: 8
Study 6439023 — intervention group
Group type: EXPERIMENTAL
Intervention: tocainide
Number of subjects: 99
Study 6439023 — intervention group
Group type: COMPARATOR
Intervention: lidocaine
Number of subjects: 99
Study 31583410 — intervention group
Group type: COMPARATOR
Intervention: Standard Parents as Teachers (PAT)
Number of subjects: 54
Study 31583410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and physical activity enhanced version (PATE)
Number of subjects: 54
Study 29604289 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg
Number of subjects: 53
Study 29604289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 26739393 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular alcohol consumption (1 to 6 drinks/week)
Number of subjects: 519
Study 24257722 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g whey protein
Number of subjects: 48
Study 24257722 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g whey protein
Number of subjects: 48
Study 24257722 — intervention group
Group type: COMPARATOR
Intervention: 10 g whey protein
Number of subjects: 48
Study 23186083 — intervention group
Group type: EXPERIMENTAL
Intervention: Preperitoneal, retromuscular lightweight monofilament polypropylene mesh
Number of subjects: 150
Study 23186083 — intervention group
Group type: COMPARATOR
Intervention: Traditional stoma without mesh
Number of subjects: 150
Study 21050973 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg) plus clopidogrel (75 mg) daily (AC group)
Number of subjects: 249
Study 21050973 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg) alone daily (A group)
Number of subjects: 249
Study 17440366 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-layer palatoplasty (Kriens technique) with intravelar veloplasty
Number of subjects: 70
Study 17440366 — intervention group
Group type: COMPARATOR
Intervention: Two-layer palatoplasty (Wardill-Kilner V-Y pushback technique) without intravelar veloplasty
Number of subjects: 70
Study 15271770 — intervention group
Group type: EXPERIMENTAL
Intervention: leflunomide (20 mg once daily) plus sulfasalazine (2 g once daily)
Number of subjects: 106
Study 15271770 — intervention group
Group type: COMPARATOR
Intervention: placebo plus sulfasalazine (2 g once daily)
Number of subjects: 106
Study 11777674 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Health Record Booklets (PHRBs) mailed to residents
Number of subjects: 12600
Study 11777674 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12600
Study 9921995 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin
Number of subjects: 100
Study 9921995 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime/amikacin (control)
Number of subjects: 100
Study 7761291 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cognitive stimulation training
Number of subjects: 78
Study 7761291 — intervention group
Group type: COMPARATOR
Intervention: Placebo (passive) activity
Number of subjects: 78
Study 7761291 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 78
Study 2086492 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg co-dergocrine mesylate (CDM)
Number of subjects: 27
Study 2086492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2086492 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 weeks of daily CDM administration
Number of subjects: 27
Study 2086492 — intervention group
Group type: COMPARATOR
Intervention: Placebo (second study)
Number of subjects: 27
Study 347364 — intervention group
Group type: EXPERIMENTAL
Intervention: Low phenylalanine diet (phase B)
Number of subjects: 6
Study 347364 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied behavior analysis techniques (differential reinforcement of other behavior and time out)
Number of subjects: 6
Study 347364 — intervention group
Group type: COMPARATOR
Intervention: Normal phenylalanine diet (phase A)
Number of subjects: 6
Study 30088545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradetrusor onabotulinumtoxinA injections (300U)
Number of subjects: 68
Study 30088545 — intervention group
Group type: COMPARATOR
Intervention: Oral oxybutynin (5mg, three times/day)
Number of subjects: 68
Study 27142046 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal faking condition
Number of subjects: 22
Study 27142046 — intervention group
Group type: EXPERIMENTAL
Intervention: Depletion condition
Number of subjects: 22
Study 27142046 — intervention group
Group type: COMPARATOR
Intervention: Baseline BIAT
Number of subjects: 22
Study 27142046 — intervention group
Group type: EXPERIMENTAL
Intervention: Both conditions (normal faking and depletion)
Number of subjects: 22
Study 25128203 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive strength training (PST) for 12 weeks, 70-80% of maximal strength, three times per week.
Number of subjects: 40
Study 25128203 — intervention group
Group type: COMPARATOR
Intervention: Matched control group maintaining daily activity levels.
Number of subjects: 40
Study 23323825 — intervention group
Group type: EXPERIMENTAL
Intervention: GMFCS previously assigned
Number of subjects: 50
Study 23323825 — intervention group
Group type: COMPARATOR
Intervention: No GMFCS score assigned
Number of subjects: 50
Study 20090909 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei subsp. Rhamnosus (LGG)
Number of subjects: 0
Study 20090909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18096810 — intervention group
Group type: EXPERIMENTAL
Intervention: Spanish Diabetes Self-Management Program (SDSMP)
Number of subjects: 567
Study 18096810 — intervention group
Group type: EXPERIMENTAL
Intervention: SDSMP with automated telephone reinforcement
Number of subjects: 567
Study 18096810 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 567
Study 16096704 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1250 mg/m2 + vinorelbine 30 mg/m2 (GV group)
Number of subjects: 114
Study 16096704 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin 50 mg/m2 + gemcitabine 1000 mg/m2 + vinorelbine 25 mg/m2 (CGV group)
Number of subjects: 114
Study 11333129 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryostatin-1 (72 h regimen)
Number of subjects: 49
Study 11333129 — intervention group
Group type: EXPERIMENTAL
Intervention: Bryostatin-1 (24 h regimen)
Number of subjects: 49
Study 9727278 — intervention group
Group type: EXPERIMENTAL
Intervention: PCR for MPB64 gene
Number of subjects: 254
Study 8054254 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol (1 g 4 times per day)
Number of subjects: 10
Study 8054254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3140403 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) at 1.5 gm protein/kg/day and 30 nonprotein calories/kg/day
Number of subjects: 66
Study 3140403 — intervention group
Group type: COMPARATOR
Intervention: Parenteral nutrition (PN)
Number of subjects: 66
Study 3140403 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN)
Number of subjects: 66
Study 3140403 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of formula given
Number of subjects: 66
Study 3140403 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with a nonprotein‐calorie‐to‐nitrogen ratio of 100:1
Number of subjects: 66
Study 1612951 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy multiple daily fractionation (MDF), using 3 daily fractions of 1.25 Gy each, up to a total dose of 37.5 Gy in 12 days.
Number of subjects: 236
Study 1612951 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy conventional fractionation (CF), for a total dose of 50 Gy/5 weeks.
Number of subjects: 236
Study 1612951 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (cystectomy alone).
Number of subjects: 236
Study 278698 — intervention group
Group type: COMPARATOR
Intervention: Professional prophylaxis
Number of subjects: 98
Study 278698 — intervention group
Group type: COMPARATOR
Intervention: Dental health care instruction
Number of subjects: 98
Study 278698 — intervention group
Group type: COMPARATOR
Intervention: Single instruction plus prophylaxis
Number of subjects: 98
Study 30531556 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia
Number of subjects: 43
Study 30531556 — intervention group
Group type: COMPARATOR
Intervention: Conscious sedation
Number of subjects: 43
Study 31570100 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 33
Study 31570100 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 33
Study 31570100 — intervention group
Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 33
Study 31570100 — intervention group
Group type: COMPARATOR
Intervention: No active medication treatment
Number of subjects: 33
Study 31570100 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-NTX
Number of subjects: 33
Study 31570100 — intervention group
Group type: EXPERIMENTAL
Intervention: General factors affecting treatment retention
Number of subjects: 33
Study 28914244 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt water rinse
Number of subjects: 30
Study 28914244 — intervention group
Group type: COMPARATOR
Intervention: Chlorhexidine rinse
Number of subjects: 30
Study 26526623 — intervention group
Group type: EXPERIMENTAL
Intervention: Toremifene 60 mg plus ADT (TOPADT)
Number of subjects: 15
Study 26526623 — intervention group
Group type: COMPARATOR
Intervention: Androgen-deprivation therapy (ADT)
Number of subjects: 15
Study 26526623 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg plus ADT (RAPADT)
Number of subjects: 15
Study 23359554 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 3006
Study 23359554 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 3006
Study 21399536 — intervention group
Group type: EXPERIMENTAL
Intervention: AAKG supplementation (3,700 mg arginine alpha-ketoglutarate per serving)
Number of subjects: 12
Study 19782786 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese III (BMI > or = 40 kg/m(2))
Number of subjects: 2324
Study 19782786 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing BMI category
Number of subjects: 2324
Study 19782786 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 2324
Study 18097109 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course intermittent chemotherapy (2EHRZ 3 /4RH 3 ) thrice weekly for 6 months
Number of subjects: 31
Study 15118032 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate (1.25 mg per twenty-four hours)
Number of subjects: 65
Study 11986765 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (1255 mg m(‐2) twice daily, days 1-14)
Number of subjects: 42
Study 11986765 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (175 mg m(‐2))
Number of subjects: 42
Study 11986765 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 42
Study 11986765 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 42
Study 9829849 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment initiated until the third year of life (Group 1)
Number of subjects: 17
Study 9829849 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic treatment initiated at age 5 years and above (Group 2)
Number of subjects: 17
Study 9829849 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated joint bleeding (>5) prior to prophylactic treatment
Number of subjects: 17
Study 8137517 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable bromocriptine 50 mg intramuscularly for 28 days (Group A)
Number of subjects: 23
Study 8137517 — intervention group
Group type: COMPARATOR
Intervention: Oral bromocriptine 7.5 mg daily for 28 days (Group B)
Number of subjects: 23
Study 2808940 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured information on all aspects of the examination (sensory, procedural and temporal components, and a coping mechanism)
Number of subjects: 60